title: Stability-indicating methods for the determination of mosapride citrate in the presence of its degradation products according to ICH guidelines.
abstract: In the present work, different spectrophotometric methods and one spectrofluorimetric method have been developed and validated for the determination of mosapride citrate in the presence of its acid-induced degradation products. The drug was subjected to stress stability study including acid, alkali, oxidative, photolytic, and thermal stress degradation. The developed spectrophotometric methods included the use of first order derivative ((1)D), derivative of ratio spectra ((1)DD), mean centring of ratio spectra (MC) and H-point standard additions (HPSAM) spectrophotometric methods. For (1)D method, the peaks amplitudes at 282.8 and 319.6 nm were measured, while for (1)DD method those at 308 nm and 323 nm were measured. Mean centring of ratio spectra method used the values at 317 nm for calibration, while for HPSAM the absorbance at 273 and 288.6 nm were used. These methods were successfully applied for determination of mosapride in the concentration range of 5-70 µg.ml(-1). The spectrofluorimetric method was based on measuring the native fluorescence of mosapride in 0.1 M NaOH using λ(excitation) 276 nm and λ(emission) 344 nm and 684 nm with linearity ranges of 50-3000 ng.ml(-1) and 50-9000 ng.ml(-1), respectively. All the developed methods were validated according to the International Conference on Harmonization (ICH) guidelines and were applied for bulk powder and dosage form. The results obtained were statistically compared to each other using one-way ANOVA testing.
authors.affiliation: Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, El-Kasr El-Aini St, 11562 Cairo, Egypt. mahahgazy@yahoo.com
authors.forename: Maha A
authors.initials: MA
authors.lastname: Hegazy
authors.forename: Ali M
authors.initials: AM
authors.lastname: Yehia
authors.forename: Azza A
authors.initials: AA
authors.lastname: Mostafa
mesh_terms: D000143:Acids / Q000378:metabolism; D001549:Benzamides / Q000032:analysis* / Q000378:metabolism / Q000592:standards; D004355:Drug Stability; D005765:Gastrointestinal Agents / Q000032:analysis* / Q000378:metabolism / Q000592:standards; D006868:Hydrolysis; D009025:Morpholines / Q000032:analysis* / Q000378:metabolism / Q000592:standards; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism / Q000592:standards; D011786:Quality Control; D012015:Reference Standards; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000191:economics / Q000379:methods*; D013053:Spectrophotometry / Q000191:economics / Q000379:methods*
chemical_list: D000143:Acids; D001549:Benzamides; D005765:Gastrointestinal Agents; D009025:Morpholines; D004364:Pharmaceutical Preparations; C062720:mosapride